TABLE 2.
Cardiovascular measures and symptoms
| All patients (N = 169) | |
|---|---|
| NT‐proBNP (ng/L) a | |
| <1000 | 32 (20.4) |
| 1000–2999 | 61 (38.9) |
| 3000–5999 | 41 (26.1) |
| >6000 | 23 (14.6) |
| eGFR (mL/min/1.73 m2) b | |
| <45 | 45 (27.9) |
| 45–59 | 44 (27.3) |
| 60–89 | 69 (42.9) |
| > 90 | 3 (1.9) |
| LVEF (%) | |
| <40 | 40 (23.7) |
| 40–49 | 37 (21.9) |
| 50–60 | 50 (29.6) |
| >60 | 18 (10.7) |
| Missing or not applicable/available | 24 (14.2) |
| Current symptoms c | |
| Shortness of breath at physical activity/exercise | 125 (74.0) |
| Shortness of breath at daily physical activity | 91 (53.8) |
| Problems with balance | 74 (43.8) |
| Pronounced fatigue | 72 (42.6) |
| Swelling of lower legs and ankles (oedema) | 64 (37.9) |
| Physical weakness | 61 (36.1) |
| Feeling disorders in the hand and/or feet | 56 (33.1) |
| Dizziness/fainting | 45 (26.6) |
Data are presented as n (%).
eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐Terminal pro B‐type Natriuretic Peptide.
a
Based on the 157 patients for whom NT‐proBNP was available.
b
Based on the 161 patients for whom eGFR was available.
c
Symptoms were recorded by the patients. Only the most prevalent symptoms are listed, and one patient may have reported more than one symptom.